Showing results (1941-1950 of 2,037) with videos related to
Sort By:
Pageof 204
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2025
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III TrialsAndrew J Armstrong, Vinnie Y T Liu, Ramprasaath R Selvaraju, et al.Science (New York, N.Y.)|April 4, 2020
Contemporaneity of Australopithecus, Paranthropus, and early Homo erectus in South AfricaAndy I R Herries, Jesse M Martin, A B Leece, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2019
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY StudyAndrew J Armstrong, Susan Halabi, Jun Luo, et al.JCO Oncology Practice|December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is NowNeal Shore, Sarah M Nielsen, Edward D Esplin, et al.The Prostate|November 15, 2023
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectivenessChanning J Paller, Pedro C Barata, Justin Lorentz, et al.International Journal of Epidemiology|March 9, 2018
Genome-wide average DNA methylation is determined in uteroShuai Li, Ee Ming Wong, Pierre-Antoine Dugué, et al.The Lancet. Gastroenterology & Hepatology|May 1, 2022
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest GroupStuart McPherson, Matthew J Armstrong, Jeremy F Cobbold, et al.Genome Research|April 14, 2018
Enduring epigenetic landmarks define the cancer microenvironmentRuth Pidsley, Mitchell G Lawrence, Elena Zotenko, et al.The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.Journal for Immunotherapy of Cancer|August 17, 2022
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trialKarim Fizazi, Margitta Retz, Daniel P Petrylak, et al.Pageof 204